The Medicines Co. (NASDAQ: MDCO) announced last week that its cholesterol-lowering medicine inclisiran, meant to be taken just twice a year, had passed a key test but offered no details. Some of those details arrived this morning.
At a medical meeting in Paris, a presentation from the test, a 1,617-patient Phase 3 study called ORION-11, did nothing to derail the expectation that inclisiran is just as safe and effective as other next-generation cholesterol fighting drugs.
However, as Xconomy reported, the data also don’t portend whether inclisiran, if approved by the FDA, will succeed commercially where two other, similar medicines—all of… Read more »
UNDERWRITERS AND PARTNERS